LONDON, March 20, 2014 /PRNewswire/ --
On Wednesday, March 19, 2014, the
US markets saw a negative sentiment with the NASDAQ Composite
closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average
ending the session at 16,222.17, down 0.70% and the S&P 500
edging 0.61% lower to finish the trading session at 1,860.77. The
losses were broad based as all the ten sectors ended the session in
negative. A number of stocks saw large movements, including
Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd
(AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla
Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM,
IMUC, IDN, and LJPC can be downloaded upon signing up at:
http://www.investor-edge.com/354-register
Sequenom Inc.'s stock finished Wednesday's session at $2.48, recording a gain of 6.44%. A total of 4.44
million shares were traded which is above the three months average
volume of 1.89 million shares. The stock vacillated between
$2.32 and $2.52 during the session.
Sequenom Inc.'s shares have gained 8.30% in the previous three
trading sessions, 15.35% in the last three months and 5.98% on YTD
basis. The S&P 500 Health Care Sector Index mapped a loss of
0.37% during the trading session and charted up 1.70% in the last
one month. Additionally, the stock is trading at the RSI of 49.43
and above its 50-day moving average of $2.37. Sign up today to read free research on
SQNM at:
http://www.investor-edge.com/354-SQNM-20Mar2014.pdf
Shares in ImmunoCellular Therapeutics Ltd edged 6.25% higher,
finishing Wednesday's session at $1.36, with 3.21 million shares traded as
compared to a three months average volume of 2.79 million shares.
The stock fluctuated between $1.29 and
$1.37 during the trading session. Shares in ImmunoCellular
Therapeutics Ltd have advanced 7.94% in the last one month, 88.55%
in the previous three months and 47.03% on YTD basis. The S&P
500 Health Care Sector Index declined 0.37% during the trading
session, while the same has charted up 1.72% in the previous three
trading sessions. Furthermore, the stock is trading at the RSI of
49.48 and above its 50-day moving average of $1.22. Sign up today to read free research on
IMUC at:
http://www.investor-edge.com/354-IMUC-20Mar2014.pdf
On Wednesday, shares in Intellicheck Mobilisa Inc. ended the day at
$1.21, up 18.63%, hitting a new
52-week high of $1.23. A total of
2.71 million shares were traded as compared to the three months
average volume of 0.88 million shares. During the session, the
stock oscillated between $1.03 and
$1.23. Intellicheck Mobilisa Inc.'s shares have rallied
76.80% in the last one month, 168.81% in the previous three months
and 142.00% on YTD basis. The S&P 500 Information Technology
Sector Index lost 0.52% during the trading session and charted up
1.14% in the last one month. Furthermore, the stock is trading at
the RSI of 66.28 and above its 50-day and 200-day moving averages
of $0.66 and $0.57, respectively. Sign up today to read free
research on IDN at:
http://www.investor-edge.com/354-IDN-20Mar2014.pdf
La Jolla Pharmaceutical Co.'s stock closed Wednesday's session at
$15.38, up 18.58% with a trading
volume of 1.31 million shares as compared to a three months average
volume of 0.47 million shares. The stock traded between
$12.66 and $15.90 during the session
and has gone up 98.45% on YTD basis. La Jolla Pharmaceutical Co.'s
shares have surged 94.93% in the last one month and 112.14% in the
previous three months. The S&P 500 Health Care Sector Index
mapped a loss of 0.37% during the trading session and charted up
8.42% in the previous three months. Moreover, the stock is trading
at the RSI of 60.53 and above its 50-day and 200-day moving
averages of $8.90 and $6.50, respectively. Sign up today to read free
research on LJPC at:
http://www.investor-edge.com/354-LJPC-20Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
Investor-Edge.com
SOURCE Investor-Edge